Q3 2024 Earnings Estimate for Omnicell, Inc. Issued By Zacks Research (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Equities research analysts at Zacks Research upped their Q3 2024 earnings per share estimates for Omnicell in a report released on Tuesday, April 16th. Zacks Research analyst M. Mondal now anticipates that the company will post earnings per share of $0.11 for the quarter, up from their prior estimate of $0.08. The consensus estimate for Omnicell's current full-year earnings is $0.10 per share.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The company had revenue of $258.85 million for the quarter, compared to analysts' expectations of $256.00 million.

A number of other research analysts have also recently commented on OMCL. Barclays started coverage on Omnicell in a research report on Wednesday, January 3rd. They issued an "underweight" rating and a $33.00 price target on the stock. Benchmark reduced their price objective on Omnicell from $42.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, February 9th. Finally, Wells Fargo & Company reduced their price objective on Omnicell from $28.00 to $26.00 and set an "equal weight" rating on the stock in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $42.20.

Omnicell Price Performance

Shares of NASDAQ OMCL traded down $0.38 during mid-day trading on Wednesday, reaching $26.27. The company had a trading volume of 412,368 shares, compared to its average volume of 550,040. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.22 and a current ratio of 2.52. Omnicell has a one year low of $25.69 and a one year high of $77.14. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -58.38 and a beta of 0.76. The business's 50-day simple moving average is $27.76 and its 200 day simple moving average is $33.05.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Counterpoint Mutual Funds LLC bought a new stake in shares of Omnicell during the first quarter worth about $300,000. Vanguard Group Inc. grew its holdings in shares of Omnicell by 8.5% during the fourth quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company's stock worth $209,653,000 after purchasing an additional 434,336 shares during the last quarter. Greenwood Capital Associates LLC grew its holdings in shares of Omnicell by 12.9% during the fourth quarter. Greenwood Capital Associates LLC now owns 12,659 shares of the company's stock worth $476,000 after purchasing an additional 1,447 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Omnicell during the fourth quarter worth about $302,000. Finally, Legal & General Group Plc grew its holdings in shares of Omnicell by 38.2% during the fourth quarter. Legal & General Group Plc now owns 567,083 shares of the company's stock worth $21,339,000 after purchasing an additional 156,734 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.